Pneumococcal Conjugate Vaccine Recommendations

Adult Populations

The Centers for Disease Control and Prevention recommends pneumococcal conjugate vaccine for all adults aged ≥65 years 1, 2
Adults with chronic heart disease, including congestive heart failure and cardiovascular diseases, should receive pneumococcal conjugate vaccine 1, 3
Adults with chronic lung disease should receive pneumococcal conjugate vaccine 1, 3
Adults with chronic liver disease should receive pneumococcal conjugate vaccine 1, 3
Adults with diabetes mellitus should receive pneumococcal conjugate vaccine 1, 3
Current smokers have 2.8-4.1 times the risk for invasive pneumococcal disease compared with adults without underlying risk conditions 3
Adults with immunocompromising conditions, such as HIV infection, congenital or acquired immunodeficiencies, iatrogenic immunosuppression, generalized malignancy, Hodgkin disease, leukemia, lymphoma, and multiple myeloma, should receive pneumococcal conjugate vaccine 1, 3
Adults with sickle cell disease or other hemoglobinopathies should receive pneumococcal conjugate vaccine 4
Solid organ transplant recipients should receive pneumococcal conjugate vaccine 4

Vaccination Schedule

For adults who have never received a pneumococcal conjugate vaccine, one dose of PCV20 alone is recommended 1, 2
For adults who previously received PPSV23 only, one dose of PCV20 at least 1 year after the last PPSV23 dose is recommended 2, 5
For adults who previously received PCV13 only, one dose of PCV20 at least 1 year after the PCV13 dose is recommended 2, 5
For adults who received both PCV13 and PPSV23, shared clinical decision-making is recommended regarding administration of PCV20, which if given should be administered ≥5 years after the last pneumococcal vaccine dose 4, 5

Special Considerations

For immunocompromised adults, the minimum interval between PCV15 and PPSV23 can be shortened to 8 weeks 2, 5
Pneumococcal vaccination has been associated with a 22% reduction in all-cause mortality among adults with cardiovascular disease or very high cardiovascular risk 3

Pneumococcal Vaccination Guidelines for High-Risk Adults

Recommendation Based on Current Guidelines

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of PCV20 for adults aged ≥65 years who previously received only PPSV23, including those with chronic medical conditions like diabetes, at least 1 year after the last PPSV23 dose 6, 7, 8, 9
Adults with chronic medical conditions, including diabetes, are eligible for PCV20 vaccination, as recommended by the ACIP 8, 9

Rationale for PCV20 Administration

Diabetes is considered a chronic medical condition that increases the risk for pneumococcal disease, according to the ACIP 9
PCV20 provides coverage against 20 pneumococcal serotypes, expanding protection beyond the previous vaccination, as stated by the ACIP 10
A 5-year interval since the last PPSV23 dose exceeds the minimum required 1-year interval between PPSV23 and subsequent PCV20, as recommended by the ACIP 11, 6

Implementation Considerations

The patient should receive a single dose of PCV20 since it has been ≥1 year since their PPSV23 dose, as recommended by the ACIP 6
No additional pneumococcal vaccines are needed after PCV20 administration in this scenario, according to the ACIP 7
This recommendation aligns with the goal of reducing morbidity and mortality from pneumococcal disease in high-risk older adults, as stated by the ACIP 8, 10

Common Pitfalls to Avoid

After receiving PCV20, no additional pneumococcal vaccines are needed, as recommended by the ACIP 11, 7
Ensure at least 1 year has passed since the last PPSV23 dose before administering PCV20, which is satisfied in this case, according to the ACIP 6, 7

Prevnar 20 Vaccination Guidelines

Adult Dosing Recommendations

The Centers for Disease Control and Prevention recommends that adults ≥65 years old receive one dose of PCV20 alone 12, 13
The Centers for Disease Control and Prevention recommends that adults 19-64 years with chronic medical conditions receive one dose of PCV20 alone 12, 13
The Centers for Disease Control and Prevention recommends that adults 19-64 years with immunocompromising conditions receive one dose of PCV20 alone 12, 13
For adults who received PPSV23 only, administer one dose of PCV20 ≥1 year after the last PPSV23 dose 13
For adults who received PCV13 only, administer one dose of PCV20 ≥1 year after the PCV13 dose 13
For immunocompromised adults who received PCV13 only, the interval can be as short as ≥1 year 13
For adults who completed the series with PPSV23 at age ≥65 years, shared clinical decision-making regarding a single dose of PCV20 ≥5 years after the last pneumococcal vaccine dose 13
For adults 19-64 years with immunocompromising conditions who received PCV13 and 1 dose of PPSV23, administer PCV20 ≥5 years after the last pneumococcal vaccine dose 13

Key Clinical Considerations

After PCV20 administration, no additional pneumococcal vaccines are needed in most scenarios, as PCV20 provides comprehensive coverage 13
Immunocompromised adults do not need shorter intervals between PCV20 doses, eliminating the complexity of sequential PCV13/PPSV23 regimens 13
Once PCV20 is administered, the pneumococcal vaccination series is complete for most patients 13

PCV20 Administration After PCV13

Recommended Intervals and Clinical Scenarios

The Centers for Disease Control and Prevention recommends administering a single dose of PCV20 ≥1 year after the PCV13 dose for adults aged 19-64 years with immunocompromising conditions, CSF leak, or cochlear implant 14, 15
The American College of Physicians notes that this is a firm recommendation, not shared decision-making, for adults aged 19-64 years with immunocompromising conditions, CSF leak, or cochlear implant 14
The Centers for Disease Control and Prevention states that once PCV20 is given, the pneumococcal vaccination series is complete and no additional doses are needed for adults aged 19-64 years with immunocompromising conditions, CSF leak, or cochlear implant 14, 15
The Centers for Disease Control and Prevention recommends administering a single dose of PCV20 ≥1 year after the PCV13 dose for adults aged 19-64 years with chronic medical conditions only 14, 15
The American Academy of Family Physicians notes that chronic conditions include diabetes, chronic heart disease, chronic lung disease, chronic liver disease, alcoholism, or cigarette smoking 14
The Centers for Disease Control and Prevention states that this completes the pneumococcal vaccine series for adults aged 19-64 years with chronic medical conditions only 14
The Centers for Disease Control and Prevention recommends administering a single dose of PCV20 ≥1 year after the PCV13 dose for adults aged ≥65 years who received PCV13 only 14, 15
The Infectious Diseases Society of America notes that this is the preferred approach to provide broader serotype coverage for adults aged ≥65 years who received PCV13 only 15
The Centers for Disease Control and Prevention states that the series is complete after PCV20, and no additional vaccines are needed for adults aged ≥65 years who received PCV13 only 14
The Centers for Disease Control and Prevention recommends administering PCV20 ≥5 years after the last pneumococcal vaccine dose for adults who received both PCV13 and PPSV23 (but PPSV23 not yet given at age ≥65) 14, 15, 16
The American College of Physicians notes that for immunocompromised patients specifically, PCV20 should be given ≥5 years after the last dose 14
The Centers for Disease Control and Prevention states that this completes the series, and no further pneumococcal vaccines are needed for adults who received both PCV13 and PPSV23 (but PPSV23 not yet given at age ≥65) 14, 16

Rationale for PCV20 After PCV13

The Centers for Disease Control and Prevention notes that conjugate vaccines like PCV20 have immunologic advantages over PPSV23, including T-cell dependent responses and immunologic memory 16, 17
The Infectious Diseases Society of America states that phase III clinical trials demonstrated PCV20 is safe and immunogenic in adults previously vaccinated with PCV13, regardless of interval (6 months to 5 years) 16

Critical Timing Intervals

The Centers for Disease Control and Prevention recommends a standard interval of ≥1 year after PCV13 for most adults 14, 15
The American Academy of Family Physicians notes that an extended interval of ≥5 years after the last dose is recommended when both PCV13 and PPSV23 were previously given 14, 15, 16
The Infectious Diseases Society of America states that immunocompromised patients should follow the same ≥1 year interval after PCV13 14, 15

Common Pitfalls to Avoid

The Centers for Disease Control and Prevention warns against giving PCV20 too soon, as the 1-year minimum interval after PCV13 must be observed for optimal response 14, 15
The American College of Physicians notes that adding PPSV23 after PCV20 is unnecessary and not recommended, as once PCV20 is administered, the series is complete 14
The Infectious Diseases Society of America states that the 5-year interval applies only when both PCV13 and PPSV23 were previously given; otherwise, the 1-year interval should be used 14, 15

Special Populations

The Centers for Disease Control and Prevention recommends the same ≥1 year interval after PCV13 for immunocompromised adults (HIV, transplant, malignancy, etc.) 14
The American Academy of Family Physicians notes that repeat doses of conjugate vaccines have been shown to be modestly immunogenic in immunocompromised patients 14

Pneumococcal Conjugate Vaccine 20-valent Administration Guidelines

Age-Based Recommendations

The Centers for Disease Control and Prevention recommends administering PCV20 to adults aged 19-49 years with immunocompromising conditions, such as HIV infection, congenital or acquired immunodeficiencies, and iatrogenic immunosuppression, as this provides broad serotype coverage and simplifies the vaccination schedule 18, 19
The Centers for Disease Control and Prevention recommends giving one dose of PCV20 to adults aged ≥65 years who are pneumococcal vaccine-naïve, regardless of underlying medical conditions 20

Risk-Based Recommendations

The Centers for Disease Control and Prevention recommends administering PCV20 to adults aged 19-64 years with chronic medical conditions, including chronic heart disease, chronic lung disease, chronic liver disease, diabetes mellitus, and alcoholism, as this provides broad serotype coverage and simplifies the vaccination schedule 20, 18
The Centers for Disease Control and Prevention recommends administering PCV20 to adults aged 19-64 years with immunocompromising conditions, including HIV infection, congenital or acquired immunodeficiencies, iatrogenic immunosuppression, generalized malignancy, and solid organ transplant recipients, as this provides broad serotype coverage and simplifies the vaccination schedule 19

Special Population: Hematopoietic Stem Cell Transplant (HSCT)

The Centers for Disease Control and Prevention recommends using a 4-dose series of PCV20 for adults who received HSCT, starting 3-6 months after HSCT, with the first 3 doses given 4 weeks apart, and the fourth dose administered at least 6 months after the third dose or at least 12 months after HSCT, whichever is later 20, 21

Timing Based on Prior Pneumococcal Vaccination

The Centers for Disease Control and Prevention recommends administering PCV20 at least 1 year after the last PPSV23 dose, and at least 1 year after the PCV13 dose, for all age groups and risk categories 18, 19

Prevnar 20 Administration Guidance

Introduction to PCV20 Administration

The Centers for Disease Control and Prevention (CDC) recommends that Prevnar 20 (PCV20) may be administered to patients who have already received both Prevnar 13 (PCV13) and Prevnar 23 (PPSV23), with a minimum interval of ≥5 years since the last pneumococcal vaccine dose, through shared clinical decision-making between the provider and patient 22, 23

Current ACIP Guidance for PCV20 Administration

The Advisory Committee on Immunization Practices (ACIP) guidelines specifically address patients who have received both PCV13 and PPSV23 with the PPSV23 dose given at age ≥65 years, recommending shared clinical decision-making for PCV20 administration 22, 23
If the decision is made to give PCV20, the interval must be ≥5 years since the last PCV13 or PPSV23 dose, as per ACIP guidelines 22, 23
The ACIP guidelines state that this represents an optional additional dose, not a required vaccination 22, 23

Key Considerations for Decision-Making

Patients with immunocompromising conditions, such as chronic renal failure, HIV infection, immunosuppressive therapy, malignancy, or other immunocompromising conditions, may benefit from the additional serotype coverage of PCV20 22, 23
The timing of PCV20 administration is critical, with a minimum interval of ≥5 years since the last pneumococcal vaccine dose required to optimize immune response 22, 23

Clinical Decision Algorithm

The CDC recommends verifying vaccination history and timing, including confirmation of both PCV13 and PPSV23 receipt, and calculation of time since last pneumococcal vaccine (must be ≥5 years) 22, 23
The CDC also recommends assessing patient risk factors, including immunocompromising conditions and high-risk chronic conditions, as part of the shared decision-making process 22, 23
If the decision is made to vaccinate, the CDC recommends administering a single dose of PCV20, with documentation that the pneumococcal vaccination series is now complete 22, 23

Important Caveats

The ACIP guidelines explicitly state that PCV20 administration is not routinely recommended for all patients who completed the PCV13/PPSV23 series, and that shared decision-making is required 22, 23
The CDC warns against administering PCV20 if <5 years have elapsed since the last PCV13 or PPSV23 dose, as this violates ACIP recommendations and may result in suboptimal immune response 22, 23

Pneumococcal Vaccination Guidelines for Adults with Chronic Lung Disease

Recommended Vaccination Options

The American College of Physicians and the Centers for Disease Control and Prevention recommend that adults aged 19-64 years with chronic lung disease, including COPD, receive either PCV20 or PCV15 as the initial pneumococcal vaccination, with PCV20 being the preferred single-dose option 24, 25
The Advisory Committee on Immunization Practices (ACIP) guidelines provide two acceptable approaches for pneumococcal vaccination in adults with chronic lung disease: administering a single dose of PCV20 or a two-dose series of PCV15 followed by PPSV23 ≥1 year later 24, 25

Clinical Rationale for COPD Patients

The Centers for Disease Control and Prevention (CDC) explicitly lists chronic lung disease, including COPD, as an indication for pneumococcal vaccination in adults aged 19-64 years, due to the increased risk of pneumococcal disease in this population 24, 25

Practical Implementation

If PCV20 is available, the CDC recommends administering it as a single dose to simplify the vaccination schedule and provide immediate comprehensive serotype coverage, completing the pneumococcal vaccination series 24, 25
If PCV20 is unavailable, the CDC recommends administering PCV15 now and scheduling PPSV23 for ≥1 year later, with the patient required to return for the second dose to complete the series 24, 25

Important Caveats

The vaccination recommendations should be reviewed again when the patient turns 65 years old, as additional doses may be indicated based on prior vaccination history 24, 25
If PCV15 is given, PPSV23 must follow to complete the series; PCV15 alone is insufficient 24, 25

What Happens at Age 65?

When the patient reaches 65 years of age, her pneumococcal vaccination needs will be reassessed, and if she received PCV20, no additional pneumococcal vaccines are typically needed at age 65 24, 25

Timing of PCV20 Administration After Pneumonia

Key Principles

The Centers for Disease Control and Prevention (CDC) recommends that PCV20 can be administered immediately once the patient has clinically recovered from the acute pneumonia episode, with no required waiting period after pneumonia itself, only intervals based on prior pneumococcal vaccination history 26, 27
The timing of PCV20 administration depends entirely on prior pneumococcal vaccination history, not on the pneumonia episode itself, according to the CDC 26, 27

Vaccination Intervals

For adults who have never been vaccinated or have only received PCV7, the CDC recommends administering PCV20 as soon as the patient has recovered from acute pneumonia, with no waiting period required beyond clinical recovery 26, 27
For adults who have previously received PPSV23 only, the CDC recommends waiting ≥1 year after the last PPSV23 dose before administering PCV20 26, 27
For adults who have previously received PCV13 only, the CDC recommends waiting ≥1 year after the PCV13 dose before administering PCV20 26, 27
For adults who have previously received both PCV13 and PPSV23, the CDC recommends waiting ≥5 years after the last pneumococcal vaccine dose (whichever was most recent) before administering PCV20 26, 27

Special Populations

For immunocompromised adults, the CDC recommends the same ≥1 year interval after prior PCV13 or PPSV23 when giving PCV20 26, 27

Practical Application

The CDC recommends confirming clinical recovery from pneumonia, obtaining vaccination history, and applying the appropriate interval before administering PCV20 26, 27
The CDC recommends administering PCV20 once interval requirements are met, and documenting completion of the pneumococcal vaccine series 26, 27

Pneumococcal Vaccination for Smokers

Indications for Vaccination

Cigarette smoking is an explicit indication for pneumococcal vaccination in adults under 65 years, with current smokers having 2.8-4.1 times the risk for invasive pneumococcal disease compared with adults without underlying risk conditions, according to the Centers for Disease Control and Prevention 28, 29
Chronic lung disease, such as Swyer-James syndrome, provides additional indication for pneumococcal vaccination, as it is listed as a qualifying condition, as recommended by the Centers for Disease Control and Prevention 28, 29

Vaccination Recommendations

The American College of Physicians and other medical organizations support the recommendation that adults under 65 with qualifying conditions, such as smoking and chronic lung disease, should receive PCV20, as stated in the Morbidity and Mortality Weekly Report 28, 29

Completion of Pneumococcal Vaccination Series After Receiving Both PCV13 and PCV20

Series Completion

Adults who have already received both PCV13 (Prevnar 13) and PCV20 (Prevnar 20) have a completed pneumococcal vaccination series and do not require any additional pneumococcal vaccine doses. 30
Administration of PCV20 finalizes the pneumococcal vaccination schedule in every clinical scenario; once PCV20 is given, no further pneumococcal vaccines (including PPSV23) are needed. 30

Advisory Committee on Immunization Practices (ACIP) Recommendations

The 2023 ACIP guidelines state that when PCV20 is used in place of any dose of PPSV23, the vaccination series is considered complete and should not be followed by additional pneumococcal vaccines. 30

Situations Not Requiring Additional Doses

An additional pneumococcal vaccine may be contemplated only after a prior regimen of PCV13 + PPSV23 (but not after PCV20) via shared clinical decision‑making for a single PCV20 dose administered ≥5 years after the last pneumococcal vaccine; this scenario does not apply to individuals who have already received PCV20. 30

Immediate Pneumococcal Vaccination for Adults 19‑64 with Smoking Risk and Unknown History

Eligibility and Indications

Preferred Vaccine Regimen

Management When Vaccination History Is Unknown

Guideline Priorities Over PPSV23

Documentation and Follow‑Up

All facts are derived from ACIP recommendations as reported in the Morbidity and Mortality Weekly Report and MMWR Recommendations and Reports.

ACIP Recommendations for the Use of PCV20 in Adults

Completion of the Pneumococcal Vaccination Series

The Advisory Committee on Immunization Practices (ACIP) states that a single dose of PCV20 provides coverage against 20 pneumococcal serotypes, elicits robust T‑cell‑dependent immunity and immunologic memory, and therefore eliminates the need for any additional pneumococcal vaccines such as PPSV23. 34
According to the 2023 ACIP guidelines, administration of PCV20 alone completes the adult pneumococcal vaccination series; no subsequent dose of PPSV23 or any other pneumococcal vaccine is recommended. 34

Timing for Adults with Prior Pneumococcal Vaccination

Adults who have previously received only PPSV23 should receive a single dose of PCV20 at least 1 year after the most recent PPSV23 dose; this PCV20 dose then completes the pneumococcal series. 34
Adults who have previously received only PCV13 should receive a single dose of PCV20 at least 1 year after the PCV13 dose; this PCV20 dose completes the series. 34
Adults who have previously received both PCV13 and PPSV23 may receive an optional single dose of PCV20 through shared clinical decision‑making if ≥ 5 years have elapsed since the last pneumococcal vaccine; the PCV20 dose then completes the series. 34

Re‑evaluation When Chronic‑Condition Adults Reach Age 65

When adults with chronic medical conditions (e.g., diabetes, chronic heart, lung, or liver disease, smoking) turn 65 years old, clinicians should reassess pneumococcal vaccination status; if the individual has only ever received PPSV23, a single dose of PCV20 should be administered to complete the series, without the need for ongoing boosters. 34